Anthrax Clinical Trial
Official title:
An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax
This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with systemic anthrax. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and survival) and serum concentrations of AIGIV (for AIGIV pharmacokinetics) and anthrax toxins from sporadic cases of systemic anthrax patients treated with AIGIV.
This study is a post-marketing requirement from the FDA to evaluate safety and clinical benefit of AIGIV administered to systemic anthrax patients as part of their medical care after exposure to Bacillus anthracis (anthrax exposure can be via inhalation, ingestion, injection). Study information (i.e. data on safety and clinical benefit evaluation of AIGIV up to Day 30 following administration) and patient samples (for assessment of AIGIV pharmacokinetics and anthrax toxin levels) will be collected (up to Day 7 following AIGIV administration) prospectively to the extent possible; however, in some cases data may be collected retrospectively (including scavenged patient samples for assessment of serum AIGIV concentration and anthrax toxin levels). Therefore, both prospective and retrospective data collection are allowed in this study to maximize the amount of information obtained from systemic anthrax patients who have been treated with AIGIV. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00114621 -
Anthrax Vaccine Clinical Trials
|
Phase 1 | |
| Recruiting |
NCT00050310 -
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
|
||
| Completed |
NCT01453907 -
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01491607 -
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
|
Phase 3 | |
| Completed |
NCT03518125 -
BARDA Securing Anthrax Immunity For the Elderly
|
Phase 2 | |
| Completed |
NCT04660201 -
Anthrax AV7909 Liquid vs Lyophilized
|
Phase 1 | |
| Completed |
NCT04320485 -
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
|
||
| Recruiting |
NCT06365073 -
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
|
||
| Completed |
NCT03877926 -
VELOCITY: An Anthrax Vaccine Clinical Study
|
Phase 3 | |
| Completed |
NCT03498027 -
Febrile Whole Blood Specimen Collection and Testing
|
||
| Terminated |
NCT00964834 -
Ph1 Study of Valortim and Doxycycline in Humans
|
Phase 1 | |
| Completed |
NCT00063843 -
Anthrax-rPA: Safety, Tolerability, Immunogenicity
|
Phase 1 | |
| Completed |
NCT01624532 -
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
|
Phase 2 | |
| Completed |
NCT04148118 -
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT05672875 -
Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
|
||
| Completed |
NCT01770743 -
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
|
Phase 2 | |
| Completed |
NCT00845650 -
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
|
Phase 1/Phase 2 | |
| Completed |
NCT01867957 -
Efficacy and Safety of Anthrax Vaccine, GC1109
|
Phase 1 | |
| Completed |
NCT00031291 -
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
|
N/A | |
| Recruiting |
NCT05997264 -
Anthrax AV7909 Boost Evaluation Study
|
Phase 2 |